Expression of secreted protein acidic and rich in cysteine in the stroma of a colorectal carcinoma is associated with patient prognosis

Annals of Coloproctology

Volumn 29, Issue 3, 2013, Pages 93-99

  Kim, Jeong Yeon ^a   Jeong, Dongjun ^a   Ahn, Tae Sung ^b   Kim, Hyung Ju ^a   Park, Doo San ^a   Park, So Yong ^a   Bae, Sang Byung ^a   Lee, Sookyoung ^a   Lee, Sung Soo ^b   Lee, Moon Soo ^b   Cho, Hyun Deuk ^a   Baek, Moo Jun ^b  

^a Department of Pathology ^*  (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Colorectal neoplasms; Osteonectin; Prognosis; SPARC

Indexed keywords

OSTEONECTIN;

ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL GROWTH; CELL INTERACTION; COLORECTAL CARCINOMA; EXTRACELLULAR MATRIX; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MEDICAL RECORD; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STROMA CELL; TISSUE MICROARRAY; TUMOR CELL;

EID: 84889773811     PISSN: 22879714     EISSN: 22879722     Source Type: Journal    
DOI: 10.3393/ac.2013.29.3.93     Document Type: Article

References (26)

1. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002;14:608-16.
2. Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial- mesenchymal transition. Oncogene 2007;26:7859-71.
3. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Ful-ford L, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004;64:3037-45.
4. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997;108:210-4.
5. Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mik-kelsen T, et al. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 1998;57:1112-21.
6. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001;159:609-22.
7. Puolakkainen PA, Brekken RA, Muneer S, Sage EH. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2004;2:215-24.
8. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006; 20:426-32.
9. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer 2008;98:1810-9.
10. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 2007;121:567-75.
11. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
12. Rosenblatt S, Bassuk JA, Alpers CE, Sage EH, Timpl R, Preissner KT. Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Bio-chem J 1997;324(Pt 1):311-9.
13. Xie RL, Long GL. Role of N-linked glycosylation in human osteonectin. Effect of carbohydrate removal by N-glycanase and site-directed mutagenesis on structure and binding of type V collagen. J Biol Chem 1995;270:23212-7.
14. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981;26(1 Pt 1):99-105.
15. Sage H, Johnson C, Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem 1984;259:3993-4007.
16. Holland PW, Harper SJ, McVey JH, Hogan BL. In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J Cell Biol 1987;105:473-82.
17. Mason IJ, Murphy D, Munke M, Francke U, Elliott RW, Hogan BL. Developmental and transformation-sensitive expression of the Sparc gene on mouse chromosome 11. EMBO J 1986;5:1831-7.
18. Sosa MS, Girotti MR, Salvatierra E, Prada F, de Olmo JA, Gallan-go SJ, et al. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 2007;7: 4123-34.
19. Smit DJ, Gardiner BB, Sturm RA. Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 2007; 121:2653-60.
20. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25.
21. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-80.
22. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
23. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 2006;66:7516-23.
24. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajo-vsky Y, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997;3:171-6.
25. Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C, et al. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 2005; 65:5123-32.
26. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overex-pression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002;21:7077-91.